Get Premium to unlock powerful stock data
NAS:BMRN (USA)   Healthcare » Biotechnology
Biomarin Pharmaceutical Inc logo

Biomarin Pharmaceutical Inc $ 75.89 -1.63 (-2.1%)

On watch
Volume:
1,516,688
Avg Vol (1m):
1,207,935
Market Cap $:
13.91 Bil
Enterprise Value $:
13.88 Bil
PE Ratio:
17.69
PB Ratio:
3.28
Warning! GuruFocus has detected 2 Severe warning signs with BMRN. Click here to check it out.
EMBED
5D 3M YTD 1Y 3Y 5Y 10Y All 10Y -%
Above Low: +NaN%
Below High: NaN%
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for BMRN (Biomarin Pharmaceutical Inc) from 1999 to Oct 17 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Biomarin Pharmaceutical stock (BMRN) PE ratio as of Oct 17 2021 is 17.69. More Details

Biomarin Pharmaceutical PE Ratio (TTM) Chart

EMBED

Biomarin Pharmaceutical PE Ratio (TTM) Historical Data

Total 1215
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Biomarin Pharmaceutical PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-10-1717.7 2021-08-1617.5
2021-10-1517.7 2021-08-1317.5
2021-10-1418.1 2021-08-1217.6
2021-10-1317.9 2021-08-1117.7
2021-10-1218.3 2021-08-1017.9
2021-10-1118.2 2021-08-0918.1
2021-10-0818.1 2021-08-0618.2
2021-10-0718.0 2021-08-0518.2
2021-10-0618.2 2021-08-0417.8
2021-10-0517.9 2021-08-0318.1
2021-10-0417.7 2021-08-0218.0
2021-10-0118.0 2021-07-3017.9
2021-09-3018.0 2021-07-2918.3
2021-09-2917.9 2021-07-2818.4
2021-09-2818.0 2021-07-2718.3
2021-09-2718.3 2021-07-2618.0
2021-09-2418.3 2021-07-2318.0
2021-09-2318.5 2021-07-2218.3
2021-09-2218.4 2021-07-2118.6
2021-09-2118.2 2021-07-2018.5
2021-09-2018.0 2021-07-1918.4
2021-09-1718.1 2021-07-1618.4
2021-09-1617.8 2021-07-1518.6
2021-09-1518.0 2021-07-1418.6
2021-09-1417.8 2021-07-1319.0
2021-09-1318.2 2021-07-1219.2
2021-09-1018.2 2021-07-0919.5
2021-09-0918.7 2021-07-0819.3
2021-09-0817.9 2021-07-0719.4
2021-09-0718.1 2021-07-0619.7
2021-09-0619.8 2021-07-0519.9
2021-09-0319.8 2021-07-0219.9
2021-09-0219.9 2021-07-0119.6
2021-09-0119.6 2021-06-3019.5
2021-08-3119.6 2021-06-2919.5
2021-08-3019.4 2021-06-2819.7
2021-08-2719.5 2021-06-2520.9
2021-08-2618.4 2021-06-2420.6
2021-08-2518.3 2021-06-2320.3
2021-08-2418.0 2021-06-2220.0
2021-08-2317.6 2021-06-2119.9
2021-08-2017.5 2021-06-1820.2
2021-08-1917.4 2021-06-1720.4
2021-08-1817.6 2021-06-1620.3
2021-08-1717.8 2021-06-1520.2

Biomarin Pharmaceutical PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Biomarin Pharmaceutical Inc logo

Business Description

Industry
Healthcare » Biotechnology » NAICS : 325412 SIC : 2834
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
Website
http://www.bmrn.com
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.